Evidence map›Paper›PMID 42892632›Full record

ArticleGene therapy2026

Statistical correlation between strength and mini-dystrophin expression in skeletal muscle after an rAAV9-mini-dystrophin gene therapy candidate in DMD

J M Walsh, A McIntosh, J Owens, C Le Guiner, A Lafoux, C Huchet, M Binks, S Neelakantan, V Farrokhi, H Neubert

Abstract read
PubMed Publisher
In one paragraph

Article in Gene therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

J M WalshPfizer Inc, Andover, MA, USA.ORCID http://orcid.org/0009-0000-6694-5574
A McIntoshPfizer Inc, Andover, MA, USA.ORCID http://orcid.org/0000-0002-4164-502X
J OwensPfizer Inc, Andover, MA, USA.
C Le GuinerNantes Université, CHU Nantes, INSERM, TaRGeT, UMR, Translational Research for Gene Therapy, Nantes, France.ORCID http://orcid.org/0000-0002-6904-2300
A LafouxTherassay Platform, Capacités, Nantes Université, Nantes, France.
C HuchetNantes Université, CHU Nantes, INSERM, TaRGeT, UMR, Translational Research for Gene Therapy, Nantes, France.
M BinksPfizer Inc, Andover, MA, USA.
S NeelakantanPfizer Inc, Andover, MA, USA.
V FarrokhiPfizer Inc, Andover, MA, USA.
H NeubertPfizer Inc, Andover, MA, USA. Hendrik.Neubert@pfizer.com.ORCID http://orcid.org/0000-0002-8476-5427

Funding

Pfizer (Pfizer Inc.) N/A
6 · The paper itself

Abstract

Duchenne muscular dystrophy (DMD) is an X-linked recessive disorder resulting from loss-of-function mutations in the dystrophin gene, leading to progressive muscle wasting and premature death. We present the mini-dystrophin protein expression-function relationship from a post-hoc analysis of mini-dystrophin quantification and function (strength) data at 3 and 6 months in biceps femoris and pectoralis muscles from a DMD rat model (DMD

Identifiers

PMID42892632

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.